Michael Roberts on Adaptin’s Technology: Repurposing the Immune System for Brain Drug Delivery
Michael Roberts, co-founder and chief executive of Adaptin Bio, provides over 25 years of knowledge in pharmaceutical research and biotech entrepreneurship. Bio-directed companies, including Corino Therapeutics and held important roles at Chelsea Therapeutics and Nektar Therapeutics. He also has a remarkable licensing record along with successful exits in the biological sector.
The Challenge of the Blood-Brain Barrier (BBB)
Roberts says that between circulation and the central nervous system (CNS) is a highly selective gatekeeper known as the blood-brain barrier (BBB), made up of sealed endothelial cells. by tight junctions, combined with astrocytes and pericytes, creating a strong barrier against most drugs. Almost all biologics and the great majority of small chemicals cannot pass it easily.
Innovative Mechanism: Immune-Cell Mediation for CNS Delivery
Rather than aiming to disturb or sidestep the BBB, Adaptin Bio’s platform, called BRiTE (Brain-targeted T Cell Engager), calls upon the body’s own immune cells to serve as transportation vehicles. The idea depends on the innate capacity of activated T cells under specific circumstances to penetrate the CNS. Therapeutic payloads, which can be small molecules, proteins, nucleic acids, or gene-editing compounds, in this system are connected with or tied to T cells; once those cells travel into the brain, the payloads are transported along and dropped at the disease site.
This method, Roberts notes, has advantages including maintaining barrier integrity (since it does not force disruption), encouraging a great range of therapeutic approaches, and allowing repeat dosing: all major differentiating factors from invasive delivery techniques or receptor-mediated transport.
Why Targeting Glioblastoma First
Adaptin Bio is first aimed at treating Glioblastoma (GBM). Roberts observes that GBM is a perfect first case for the BRiTE platform due to its heterogeneity, immune-suppressive character of its microenvironment, and its placement behind the BBB. Through the BRiTE platform, the firm hopes to overcome T-cell exhaustion and other Mechanisms preventing conventional immunotherapies in GBM.
Furthermore, the modular character of BRiTE enables simultaneous delivery of several payloads, such as checkpoint inhibitors or alternative T-cell engagers, therefore tackling the varied antigen environment of GBM.
Broader Potential Beyond Oncology
Michael Roberts notes that the BRiTE platform offers promise for a range of neurodegenerative and neuroinflammatory disorders, even though brain cancer continues to be the centre of attention. It includes Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. This raises the possibility of disease-modifying therapies instead of merely symptomatic ones.
Next-Steps: Milestones and Challenges Ahead
Adaptin Bio plans to start its first-in-human experiment with candidate APTN-101, an EGFRviii × CD3 T-cell engager, over the following 12 to 24 months and foster strategic collaborations for payload licensing. The firm is also building its intellectual property portfolio and identifying the manufacturing and regulatory channels for a platform approach. Still, Michael Robert admits the difficulties included in new technologies like improving healthcare through CAD are increasingly relevant in this context, offering precision modeling and simulation tools that can streamline manufacturing and enhance the reliability of platform-based drug delivery systems.
Vision for the Next Decade
Roberts anticipates the BRiTE platform transforming CNS treatment by converting the BBB from a barrier into a gateway in five to ten years hence. Customized, patient-specific delivery approaches, including immune cells, therapeutic payloads and dose schedules adjusted to brain area, stage of disease, and biomarker profiles, are what he sees.
Such a change would herald a new age of exact neurology and neuro-oncology wherein previously untreatable diseases become under control via immune-guided distribution over the protective barrier of the brain. Adaptin Bio and Michael Roberts are essentially promoting a brave new paradigm: one in which the immune system itself becomes the means for crossing one. One of the most difficult frontiers of medicine, the brain.
